KILITCH DRUGS (INDIA) Financial Statement Analysis
|
||
|
The Revenues of KILITCH DRUGS (INDIA) have increased by 10.58% YoY .
The Earnings Per Share (EPS) of KILITCH DRUGS (INDIA) has increased by 35.32 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
KILITCH DRUGS (INDIA) Last 5 Annual Financial Results
[BOM: 524500|NSE : KILITCH]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹154 Cr | ₹140 Cr | ₹114 Cr | ₹69 Cr | ₹53 Cr |
| Expenses | ₹130 Cr | ₹122 Cr | ₹104 Cr | ₹63 Cr | ₹53 Cr |
| Operating Profit (Excl OI) | ₹24 Cr | ₹18 Cr | ₹11 Cr | ₹5.32 Cr | ₹-0.01 Cr |
| Other Income | ₹4.48 Cr | ₹2.92 Cr | ₹2.91 Cr | ₹2.67 Cr | ₹4.55 Cr |
| Interest | ₹6.04 Cr | ₹5.08 Cr | ₹1.33 Cr | ₹0.88 Cr | ₹0.94 Cr |
| Depreciation | ₹3.35 Cr | ₹3.55 Cr | ₹2.47 Cr | ₹1.99 Cr | ₹2.00 Cr |
| Profit Before Tax | ₹19 Cr | ₹12 Cr | ₹9.61 Cr | ₹5.12 Cr | ₹1.61 Cr |
| Profit After Tax | ₹14 Cr | ₹8.28 Cr | ₹6.21 Cr | ₹3.77 Cr | ₹0.84 Cr |
| Consolidated Net Profit | ₹15 Cr | ₹10 Cr | ₹7.37 Cr | ₹3.67 Cr | ₹0.84 Cr |
| Earnings Per Share (Rs) | ₹9.08 | ₹6.71 | ₹4.73 | ₹2.37 | ₹0.55 |
| PAT Margin (%) | 8.79 | 5.93 | 5.44 | 5.48 | 1.58 |
| ROE(%) | 8.43 | 5.86 | 4.73 | 3.09 | 0.71 |
| ROCE(%) | 13.30 | 10.26 | 7.26 | 4.40 | 1.95 |
| Total Debt/Equity(x) | 0.18 | 0.15 | 0.15 | 0.12 | 0.11 |
Key Financials |
||
| Market Cap | : | ₹ 523.4 Cr |
| Revenue (TTM) | : | ₹ 157.5 Cr |
| Net Profit(TTM) | : | ₹ 14.1 Cr |
| EPS (TTM) | : | ₹ 8.8 |
| P/E (TTM) | : | 37.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| KILITCH DRUGS (INDIA) | 0.6% | 5.4% | -8% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 1.7% | 45.7% |
| CIPLA | 1.7% | 0.5% | 23.7% |
| DR REDDYS LABORATORIES | 5.7% | 12.4% | 18.5% |
| ZYDUS LIFESCIENCES | -1.4% | 3.1% | 44.8% |
| DIVIS LABORATORIES | -0.1% | -2.2% | 56.9% |
| MANKIND PHARMA | 4.2% | 9.8% | 49.8% |
| TORRENT PHARMACEUTICALS | 2.2% | 10.6% | 61.7% |
| LUPIN | 4.1% | 5.1% | 71.7% |
KILITCH DRUGS (INDIA) Revenues
[BOM: 524500|NSE : KILITCH]
| Y-o-Y | 10.58 % |
| 5 Yr CAGR | 30.44 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹154 Cr | 10.58 | |
| Mar2023 | ₹140 Cr | 22.20 | |
| Mar2022 | ₹114 Cr | 66.71 | |
| Mar2021 | ₹69 Cr | 28.51 | |
| Mar2020 | ₹53 Cr | - | |
KILITCH DRUGS (INDIA) Operating Profit
[BOM: 524500|NSE : KILITCH]
| Y-o-Y | 36.84 % |
| 5 Yr CAGR | Positive |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹24 Cr | 36.84 | |
| Mar2023 | ₹18 Cr | 68.82 | |
| Mar2022 | ₹11 Cr | 97.59 | |
| Mar2021 | ₹5.32 Cr | Positive | |
| Mar2020 | ₹-0.01 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 23.78 % |
| 5 Yr CAGR | Positive |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 15.72% | 23.78 | |
| Mar2023 | 12.7% | 38.19 | |
| Mar2022 | 9.19% | 18.43 | |
| Mar2021 | 7.76% | Positive | |
| Mar2020 | -0.02% | - | |
KILITCH DRUGS (INDIA) Profit After Tax
[BOM: 524500|NSE : KILITCH]
| Y-o-Y | 39.75 % |
| 5 Yr CAGR | 104.06 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹15 Cr | 39.75 | |
| Mar2023 | ₹10 Cr | 41.82 | |
| Mar2022 | ₹7.37 Cr | 100.68 | |
| Mar2021 | ₹3.67 Cr | 335.99 | |
| Mar2020 | ₹0.84 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 48.23 % |
| 5 Yr CAGR | 53.58 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 8.79 % | 48.23 | |
| Mar2023 | 5.93 % | 9.01 | |
| Mar2022 | 5.44 % | -0.73 | |
| Mar2021 | 5.48 % | 246.84 | |
| Mar2020 | 1.58 % | - | |
KILITCH DRUGS (INDIA) Earnings Per Share (EPS)
[BOM: 524500|NSE : KILITCH]
| Y-o-Y | 35.32 % |
| 5 Yr CAGR | 101.57 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹9.08 | 35.32 | |
| Mar2023 | ₹6.71 | 41.86 | |
| Mar2022 | ₹4.73 | 99.58 | |
| Mar2021 | ₹2.37 | 330.91 | |
| Mar2020 | ₹0.55 | - | |
KILITCH DRUGS (INDIA) Return on Capital Employed (ROCE)
[BOM: 524500|NSE : KILITCH]
| Y-o-Y | 29.63 % |
| 5 Yr CAGR | 61.60 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 13.3% | 29.63 | |
| Mar2023 | 10.26% | 41.32 | |
| Mar2022 | 7.26% | 65.00 | |
| Mar2021 | 4.4% | 125.64 | |
| Mar2020 | 1.95% | - | |
KILITCH DRUGS (INDIA) Share Price vs Sensex
| Current Share Price | : | ₹325.1 |
| Current MarketCap | : | ₹ 523.4 Cr |
| Updated EOD on | : | Dec 20,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| KILITCH DRUGS (INDIA) | 0.6% |
5.4% |
-8% |
| SENSEX | -5% |
0.6% |
9.2% |
KILITCH DRUGS (INDIA) related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about KILITCH DRUGS (INDIA) Financials
How the annual revenues of KILITCH DRUGS (INDIA) have changed ?
The Revenues of KILITCH DRUGS (INDIA) have increased by 10.58% YoY .
How the Earnings per Share (EPS) of KILITCH DRUGS (INDIA) have changed?
The Earnings Per Share (EPS) of KILITCH DRUGS (INDIA) has increased by 35.32 % YoY .
Check out Intrinsic Value of Peers of KILITCH DRUGS (INDIA)
Compare Stock Analytics of Peers of KILITCH DRUGS (INDIA)
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
